Wesana Health Granted US FDA Pre-IND Meeting for SANA-013
Wesana Health Holdings (CSE: WESA; OTCQB: WSNAF) announced a pre-IND meeting with the U.S. FDA for its therapy SANA-013 targeting Traumatic Brain Injury (TBI) related major depressive disorder (MDD). Scheduled for March 11, 2022, this meeting will provide feedback on the company's toxicology program before initiating a Phase I clinical trial, expected late 2022. CEO Daniel Carcillo emphasized the urgency for effective treatments, noting existing therapies achieve only a 30-40% success rate.
Wesana aims to enhance neuroplasticity and neurogenesis using a combination of psilocybin and CBD.
- FDA granted pre-IND meeting to discuss SANA-013.
- Phase I clinical trial expected to start late 2022.
- SANA-013 targets a significant unmet need in treating TBI-related MDD.
- Existing antidepressant therapies have only a 30-40% success rate.
- Limited evidence supporting efficacy of current antidepressants for post-TBI depression.
The meeting is scheduled for March 11, 2022
CHICAGO and TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, is pleased to announce that the U.S Food and Drug Administration (U.S. FDA) granted the Company’s request for a pre-IND (Investigational New Drug) meeting to discuss the novel therapy and proprietary protocol of SANA-013 for the treatment of Traumatic Brain Injury (TBI) related major depressive disorder (MDD).
In the pre-IND meeting, the Company expects to receive feedback from the FDA on its toxicology program and research to-date, in advance of IND clearance and initiation of the Phase I clinical trial, currently anticipated to occur in late 2022.
“This is a thrilling milestone in my nearly-decade long effort to find and advocate for treatments that provide hope to brain injury survivors,” said Daniel Carcillo, Wesana founder and CEO. “People who are suffering with severe TBI-related depression have a fivefold increase in suicide attempts and are 3 to 4 times more likely to die by suicide1 2. They deserve to have the best diagnostics and treatment options available to them, including a pharmaceutical option that doesn’t exasperate symptomology. We look forward to being able to move SANA-013 to a Phase I clinical trial as soon as possible.”
While there are a number of available therapies to treat depression, the success rate of antidepressants is only approximately 30 to
Wesana’s drug development program looks to utilize combination therapy to treat migraine and the symptoms associated with TBI, such as depression. By utilizing psilocybin and cannabidiol (“CBD”), a combination therapy of compounds with demonstrated effectiveness, SANA-013, is targeted to improve neuroplasticity and neurogenesis while acting as an anti-neuroinflammatory. In contrast to therapist assisted, single dose therapy, where a large dose of psilocybin is administered in clinic, which has exhibited poor durability and waning effects beginning as early as a few weeks post administration, SANA-013 utilizes a loading dose of psilocybin followed by self-administered maintenance doses of psilocybin and CBD to provide more sustained effects and benefit over time.
Mark A. Wingertzahn, Wesana’s Chief Scientific Officer said, “The data generated, and progress across Wesana’s drug development portfolio continues to exceed our expectations. This upcoming year is going to be important for Wesana as we continue to move through our development program with SANA-013 and have additional discussions on the development strategy and importance of this therapy with regulators in the U.S. and abroad.”
Please refer to the Company’s management’s discussion and analysis dated November 29, 2021, available on the Company’s profile on www.sedar.com for additional information as to the Company’s drug development program and the steps required to be completed for the Company to be able to commence phase I clinical trials.
About Wesana Health
Wesana Health helps people transcend barriers in mental health and performance. We innovate in care development through our therapies and proprietary protocols, and in care delivery through activating a new multidisciplinary, technology-supported clinical model. Learn more at www.wesanahealth.com.
________________________
1 Juengst SB, Kumar RG, Wagner AK. A narrative literature review of depression following traumatic brain injury: prevalence, impact, and management challenges. Psychol Res Behav Manag. 2017;10:175-186.
2 Oquendo MA, Friedman JH, Grunebaum MF, Burke A, Silver JM, Mann JJ. Suicidal behavior and mild traumatic brain injury in major depression. J Nerv Ment Dis. 2004;192(6):430-4.
3 Eaton WW, PI A, Kessler RC. The population dynamics of mental disorders Eaton WW, ed Public Mental Health. Oxford University Press, 2012:125-150.
4 Bombardier CH, Fann JR, Temkin NR, Esselman PC, Barber J, Dikmen SS. Rates of major depressive disorder and clinical outcomes following traumatic brain injury. JAMA. 2010;303(19):1938-45.
5 Robert S. Traumatic brain injury and mood disorders. Ment Health Clin. 2020;10(6):335-345.
FAQ
What is SANA-013 by Wesana Health?
When is the pre-IND meeting for SANA-013 scheduled?
What are the expected outcomes of the SANA-013 clinical trial?
What is the significance of the FDA's pre-IND meeting for investors?
How effective are existing therapies for TBI-related depression?
